Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2015 Jun 1.

Published in final edited form as: Circulation. 2012 Nov 26;127(1):96–103. doi: 10.1161/CIRCULATIONAHA.112.136101

Table 2.

Lipid Changes By Drug Assignment and Myalgia Status

	Total Sample		Myalgic Sample
	ATOR (n=203)	PL (n=217)	ATOR (n=19)	PL (n=10)
Δ Total-C (mg/dL)	−65.3(−70.1,−60.5)^*	2.7(−0.2,5.6)	−73.9(−88.0,−59.8)^*	12.2(0.0,24.4)
Δ LDL-C (mg/dL)	−59.0(−63.4,−54.6)^*	0.9 (−1.8,3.6)	−70.6(−83.5,−57.7)^*	10.1(−1.4,21.6)
Δ HDL-C (mg/dL)	−0.8(−2.0,0.4)	0.4(−0.7,1.5)	0.2(−4.3,4.7)	−3.4(−9.1,2.3)
Δ TRIG (mg/dL)	−28.3(−34.4,−22.3)^*	3.5(−3.1,10.1)	−18.2(−28.0,−8.4)^*	16.5(−12.3,45.3)

Data are presented as point estimates and 95% confidence intervals for atorvastatin (ATOR) vs. placebo (PL)

subjects in the entire sample and only in subjects classified as myalgic. Δ = absolute change from pre-to-post

study; C = cholesterol; LDL = low-density lipoprotein; HDL = high-density lipoprotein; TRIG = triglycerides.

^*

indicates significant change from baseline at p < 0.01; there were no differences between myalgic and nonmyalgic subjects within a treatment group.